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 Introduction 
 In the original descriptions of schizophrenia, negative 
symptoms were considered to be defining characteristics 
of the illness  [1] . In the second half of the 20th century, 
research focused mainly on positive symptoms, but inter-
est in negative symptoms has developed in a very dynam-
ic fashion since the 1980s when a standardized assess-
ment first became available  [2] . The term ‘negative symp-
toms’ was conceived because these symptoms are thought 
to reflect the absence or reduction of normal brain func-
tion  [3] . Regarding negative symptoms of schizophrenia, 
this reduction manifests itself in phenomena that include 
avolition, anhedonia, affective flattening and poverty of 
speech. There is conclusive evidence that negative symp-
toms contribute significantly to long-term morbidity and 
poor functional outcome  [4, 5] . At the same time, cur-
rently available treatments have at best modest impact on 
negative symptoms  [6] . Thus, negative symptoms are 
considered to have high priority in treatment develop-
ment  [7] .
 Kraepelin  [1] considered a characteristic disorder of 
volition to be specific to schizophrenia and did not ob-
serve this phenomenon in patients with manic-depres-
sive disorder. In the last 20 years, some authors have em-
phasized the difference between primary negative symp-
toms of the schizophrenic illness and secondary 
symptoms caused by depression, side effects of medica-
tion or deprivation  [8, 9] . The former have been conceived 
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 Abstract 
 Negative symptoms have been considered to be specific to 
schizophrenia or a subtype of schizophrenia: the deficit syn-
drome. In other words, these symptoms have been consid-
ered to be categorically different from other forms of human 
behavior and experience, whether they occur in healthy per-
sons or patients with other psychiatric disorders. In this pa-
per, we advocate a dimensional approach to negative symp-
toms, which is supported by two main arguments. First,
enduring negative symptoms can even be observed in a va-
riety of psychiatric disorders and they are not specific to 
schizophrenia. Second, we review evidence that negative 
symptoms show a continuous distribution from apparently 
healthy subjects to those with a fully developed clinical syn-
drome. Although the evidence does not allow for a definite 
decision concerning the dimensional distribution of nega-
tive symptoms, it certainly justifies exploring a dimensional 
approach with respect to its clinical and scientific utility. Un-
derstanding negative symptoms as a variation of normal 
mental processes will strengthen the development of neu-
rocognitive models and treatment approaches. 
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to be more enduring and particularly difficult to treat. 
Importantly, these symptoms have been thought to be 
specific to schizophrenia  [10, 11] . This approach has been 
taken further, leading to the definition of a deficit syn-
drome, which largely consists of persistent negative 
symptoms  [12] . It has been suggested that this syndrome 
reflects a separate disease entity within the schizophrenia 
spectrum  [13] . A concept underlying these distinctions is 
that primary negative symptoms are specific to schizo-
phrenia or a subtype of schizophrenia and reflect par-
ticular neurobiological mechanisms. In other words, the 
negative symptoms in schizophrenia are considered to be 
categorically different from other forms of human behav-
ior and experience, whether they occur in ‘healthy’ per-
sons or patients with other psychiatric disorders.
 In this paper, we would like to advocate a different ap-
proach to negative symptoms based on dimensional ap-
proaches to psychopathology. This approach rests on two 
main arguments. First, negative symptoms can be ob-
served in a wide variety of neuropsychiatric disorders, in 
particular on a mood-psychotic disorder continuum, and 
they are therefore not specific to schizophrenia. Second, 
negative symptoms show a continuous distribution from 
variations in apparently healthy subjects over subclinical 
at-risk states up to full-blown clinical syndromes. A di-
mensional approach will have important implications for 
research on the etiology and treatment of negative symp-
toms. Before we consider these arguments in detail, we 
briefly review the key components of negative symptoms.
 The Structure of Negative Symptoms in 
Schizophrenia 
 Although negative symptoms often appear conjointly, 
recent research has emphasized their multidimensional 
structure  [14] . This is an important issue because the dif-
ferent dimensions might have different underlying patho-
physiological mechanisms and might require different 
treatment approaches. The most comprehensive assess-
ment instrument for negative symptoms is the Scale for the 
Assessment of Negative Symptoms (SANS), which consists 
of five subscales addressing affective flattening, alogia, 
avolition/apathy, anhedonia/asociality and attentional 
impairment  [2, 7] . Other instruments tend to have a nar-
rower focus and deemphasize some of these subscales. The 
Positive and Negative Syndrome Scale is also suitable for 
the assessment of negative symptoms, although problems 
with the original negative subscale have repeatedly been 
shown  [15, 16] . These problems can be circumvented when 
a modified negative subscale or a negative factor score is 
used  [17] . Another prominent instrument is the Schedule 
for the Deficit Syndrome, which specifically addresses pri-
mary and enduring negative symptoms (see discussion of 
the deficit syndrome concept below)  [18] .
 Recently, the MATRICS (Measurement and Treat-
ment Research to Improve Cognition in Schizophrenia) 
Consensus Development Conference on Negative Symp-
toms agreed on a set of relevant dimensions, which in-
clude blunted affect, alogia, asociality, anhedonia and 
avolition  [19] . These dimensions form the basis for two 
assessment instruments, for which initial validation data 
have recently been published. The resulting Brief Nega-
tive Symptom Scale is a 13-item instrument primarily for 
use in clinical trials  [20] . The Clinical Assessment Inter-
view for Negative Symptoms aims at a comprehensive as-
sessment of negative symptoms including objective mea-
sures of behavior and subjective patient experience  [21] .
 With respect to relevant scale dimensions, it has to be 
noted that negative symptoms and cognitive impairment 
are now conceived of as separate symptom dimensions 
that are only moderately correlated  [22] . The attentional 
impairment subscale of the SANS has been found to be 
more closely associated with cognitive impairment and is 
therefore usually excluded from analyses  [23] . For the 
same reason, newer instruments for the assessment of 
negative symptoms do not include items specifically ad-
dressing cognition.
 A number of statistical approaches have been em-
ployed to address the structure underlying comprehen-
sive negative symptom assessments  [14, 24] . The individ-
ual items can broadly be summarized under two main 
factors ( fig. 1 ). The factor ‘diminished expression’ con-
sists of the affective flattening/blunted affect and alogia 
subscales. The second main factor encompasses the avoli-
tion/apathy and anhedonia/asociality subscales and has 
received a number of designations including amotivation 
and avolition. However, we suggest that apathy might be 
the most helpful description. If defined as a quantitative 
reduction in goal-directed behavior, the term apathy has 
the advantage not to invoke underlying mechanisms that 
are difficult to define  [25] .
 It has to be noted that anhedonia in the strict sense 
does not seem to be a core negative symptom. The experi-
ence of pleasure in response to rewarding events has con-
sistently been shown to be preserved in patients with 
schizophrenia, while they seem less capable of anticipat-
ing these experiences  [26] . The assessment of anhedonia 
by interview or questionnaire has generally focused on 
the latter aspect, which might be the reason why patients 
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with schizophrenia consistently have higher scores. For 
example, the SANS anhedonia items do not primarily ad-
dress the pleasurable experience itself, but the amount of 
and interest in certain activities. Therefore, the subsump-
tion of these items rating anticipatory anhedonia under 
the apathy factor has high face validity. Newer instru-
ments attempt to assess both anticipatory and consum-
matory anhedonia, but whether these can be reliably dif-
ferentiated remains to be seen  [20, 27] .
 Thus, there is a general consensus on the negative symp-
tom dimensions, which include blunted affect, alogia, aso-
ciality and avolition. The role of anhedonia is a matter of 
current debate. In addition, there is emerging evidence 
that these dimensions can be subsumed under two factors, 
namely diminished expression and apathy. It has to be kept 
in mind that these two broader dimensions are moderate-
ly correlated. Whether this type of differentiation will be 
of clinical value cannot be definitely answered at the mo-
ment. However, it already provides a basis for developing 
neurocognitive accounts of negative symptoms.
 A critical issue with respect to the assessment of nega-
tive symptoms is how to separate them from depressive 
and extrapyramidal symptoms. There is clearly an over-
lap between negative symptoms and depressive symp-
toms such as retardation and lack of energy  [28] . How-
ever, it has been convincingly shown that this is not the 
case when employing the Calgary Depression Scale, 
which has been specifically developed to assess depres-
sion in patients with schizophrenia  [29, 30] . The overlap 
of negative and extrapyramidal symptoms has repeatedly 
been shown in earlier studies, but has received less atten-
tion with the introduction of modern atypical antipsy-
chotic drugs  [31, 32] . However, an assessment of extrapy-
ramidal symptoms should complement studies on nega-
tive symptoms even in samples not diagnosed with 
schizophrenia.
 Negative Symptoms along a Mood-Psychotic 
Disorder Continuum 
 The question whether negative symptoms are specific 
to schizophrenia is a main topic of current discussions 
about the Kraepelinian dichotomy between dementia 
praecox and manic-depressive disorders  [33] . The valid-
ity of a dichotomic classification has been challenged on 
the grounds of clinical data, but also from a genetic and 
neuroscientific perspective  [34, 35] . While Kraepelin did 
not employ the term ‘negative symptoms’, he clearly con-
sidered a disorder of volition as characteristic of schizo-
phrenia  [1] . While the concept of avolition has also been 
linked to executive dysfunction  [36] , Kraepelin himself 
and recent authors have related this concept to reduced 
motivation for goal-directed behavior rather than its im-
plementation  [24] . More recent attempts to differentiate 
schizophrenia and affective disorders have also relied on 
the alleged specificity of negative symptoms in addition 
to first-rank symptoms.
 A first group of studies has addressed the question 
whether negative symptoms occur in affective disorders 
and whether instruments for assessing these symptoms 
show a comparable factor structure in these populations. 
These studies have shown that negative symptoms occur 
in affective disorders and can be assessed with rating 
scales originally developed for patients with schizophre-
nia  [37, 38] . In addition, factor-analytic studies in patients 
have provided evidence that a negative symptom factor 
emerges in subjects with affective disorders  [39–41] . Most 
of these studies have employed relatively broad inclusion 
criteria either according to diagnosis (e.g. schizophrenia 
+ bipolar disorder) or symptom (e.g. at least one psychot-
ic symptom). Despite the variation in inclusion criteria 
and psychopathological assessment, a negative symptom 
factor emerges consistently and can be separated from a 
depressive symptom factor. A comparable factor struc-
ture has also been found when only patients with bipolar 
disorder were investigated  [42] . Nevertheless, it is a mat-
ter of debate whether negative symptoms can be reliably 
Blunted affect
Alogia
Asociality
Avolition
Anhedonia
Apathy
Diminished expression
 Fig. 1. Overview of the negative symptom subscales that are as-
sessed by current methods. As depicted, these subscales can be 
subsumed under 2 factors, ‘diminished expression’ and ‘apathy’, 
while the status of anhedonia remains a matter of debate. 
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differentiated from depressive symptoms in cross-sec-
tional studies  [38, 43] .
 An alternative approach to resolve this discrepancy has 
suggested that only some negative symptoms might be spe-
cific to schizophrenia, while others are not. In a detailed 
psychopathological analysis, Mundt et al.  [44] compared 
patients with schizophrenia, depression, neurosis and dia-
betes mellitus. As one would expect, global negative symp-
toms occurred most frequently in the schizophrenia group, 
but they were also observed in all the other three groups. 
Further analysis showed that language disturbance and 
thought disorder were rather specific to schizophrenia, but 
core negative symptoms such as social withdrawal, affec-
tive flattening and loss of motivation were not.
 These problems clearly suggest that other ways of nar-
rowing the definition of negative symptoms might be 
needed to increase their specificity to schizophrenia. To 
address this issue, a distinction between primary and sec-
ondary negative symptoms was introduced  [8] . Primary 
negative symptoms are considered to be reflections of the 
schizophrenic disease process, while secondary negative 
symptoms are caused by depression, side effects of medi-
cation or social deprivation. According to this concept, 
secondary negative symptoms can clearly occur in affec-
tive disorders, while primary negative symptoms are con-
sidered to be characteristic of schizophrenia  [10, 11] . How-
ever, a number of studies have shown that it is very diffi-
cult to clinically arrive at a reliable distinction between 
primary and secondary negative symptoms  [45, 46] . Dif-
ferentiation seems to be feasible in neuroleptic-naïve first-
episode patients, but even in this group the relationship 
between negative symptoms and other dimensions be-
comes considerably more complex at discharge  [47] . Em-
pirical validation has also come from drug withdrawal 
paradigms, which are not suitable for clinical practice or 
even most research settings  [9] . These practical problems 
have led the MATRICS committee on negative symptoms 
to regard the primary/secondary distinction as not essen-
tial for clinical trials targeting negative symptoms  [7] .
 A second distinction has been made between transient 
and enduring negative symptoms, which are easier to dis-
tinguish. Negative symptoms of more than 1-year dura-
tion seem to be more specific to schizophrenia regardless 
of the primary/secondary distinction  [43, 48] . However, 
it has to be noted that even in these studies, up to 40% of 
patients with major depressive disorder showed enduring 
negative symptoms. This has been interpreted as reflect-
ing residual depressive symptoms, but there is mainly in-
direct evidence for this hypothesis. In a longitudinal 
study with a 10-year follow-up, Herbener and Harrow 
 [49] have shown that although enduring negative symp-
toms are most common in schizophrenia, they are not 
specific and often occur in other psychotic and affective 
disorders. Importantly, the relationship to clinical and 
outcome variables seems similar in schizophrenia and 
other disorders  [50] , which casts some doubt on the re-
sidual depression hypothesis. Moreover, the impact of 
negative symptoms and functional outcome on mood 
disorders would emphasize their clinical relevance to 
nonschizophrenic disorders. Brieger et al.  [51] employed 
factor analysis on a broad array of psychopathological 
and outcome variables in patients with bipolar disorder. 
They found a functioning/disability factor which concur-
rently loaded on negative symptoms and low functioning. 
In conjunction with the respective studies in schizophre-
nia samples, these studies suggest a high functional rel-
evance of negative symptoms across a mood-psychotic 
disorder spectrum, but further studies are clearly needed.
 In the context of the discussion on the specificity of 
primary and enduring negative symptoms, the Maryland 
group suggested that these symptoms might not be spe-
cific to schizophrenia in general, but to a subtype of the 
illness they termed ‘deficit syndrome’  [12] . Deficit syn-
drome schizophrenia is conceptualized as being categor-
ically different from nondeficit forms, i.e. it is thought to 
define a separate disease entity  [13] . While there is a con-
siderable body of research employing this concept, we 
will focus on studies with a primary focus on psychopa-
thology. Few studies have employed taxometric analysis 
as developed by Meehl to differentiate a categorical from 
a dimensional distribution of negative symptoms in pa-
tients with schizophrenia  [52] . Blanchard et al.  [53] found 
support for a distinct patient group with primary and en-
during negative symptoms. However, Cuesta et al.  [54] 
have not found stable taxa or classes in a large sample of 
patients with psychotic disorders. Another critical find-
ing is the occurrence of the deficit syndrome in disorders 
other than schizophrenia. The original definition of the 
deficit syndrome requires a diagnosis of schizophrenia. 
However, several researchers have found a surprisingly 
high rate of primary and enduring negative symptoms 
fulfilling all other deficit syndrome criteria in affective 
disorders  [55–57] . Möller et al.  [58] found considerably 
lower rates of the deficit syndrome in patients with affec-
tive disorders. Despite the conflicting findings, these re-
sults have cast some doubt on the notion that the deficit 
syndrome only occurs in patients with schizophrenia.
 Thus, while the reviewed approaches to negative symp-
toms have certainly refined the concept, there remains 
doubt as to whether specificity to schizophrenia can be 
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reached. We suggest that these findings – including those 
relating to the deficit syndrome – can be parsimoniously 
accounted for in a multidimensional model of the mood-
psychotic disorder spectrum. One example of this type of 
model has been developed by van Os, who defines five (or 
six) dimensions for this disorder spectrum: positive, neg-
ative, cognitive, manic and depressive symptoms  [59, 60] . 
In this concept, a patient with an affective disorder fulfill-
ing deficit syndrome criteria can be viewed as having a 
high expression on the affective and negative dimensions, 
although this co-occurrence might not be common 
( fig. 2 a). Also, the arguments raised by the proponents of 
the deficit syndrome, claiming that it is not a more severe 
form of schizophrenia, can be addressed in a multidimen-
sional model. These authors have clearly demonstrated 
that primary and enduring negative symptoms do not go 
along with more severe psychotic symptoms and take this 
as evidence that the deficit syndrome is not just a more 
severe form of schizophrenia  [61] . However, this argument 
mainly holds against a unidimensional severity spectrum. 
The dissociation between negative and other symptoms 
can well be accounted for in a multidimensional approach 
in which negative symptom expression can be high inde-
pendently of other symptom dimensions ( fig. 2 b).
 Negative Symptoms in the General Population 
 In the previous section, we have discussed to what ex-
tent negative symptoms occur in disorders other than 
schizophrenia, i.e. whether there is a continuum of nega-
tive symptoms across disease categories. In the present 
section, we address the question whether such a continu-
um can also be described between people diagnosed as 
having schizophrenia and subjects without any psychiat-
ric disorder. Schizophrenic symptoms have been consid-
ered the paradigmatic case for experiences and behavior 
that are fundamentally and categorically different from 
‘normal’ experience and behavior. However, a large body 
of research has been accumulated over the last 20 years 
that provides clear evidence for the occurrence of psy-
chotic symptoms in people not diagnosed as having a psy-
chiatric disorder  [62] .
 Johns and van Os  [63] describe two conceptual ap-
proaches to defining a continuum along a symptom di-
mension. The first approach holds that in a subdisorder 
range, symptoms can occur in an attenuated form. These 
attenuated symptoms are subsumed under the term 
‘schizotypal’. For example, delusions as a full-blown 
symptom would be replaced by magical ideation or sus-
piciousness as attenuated symptoms. In the second ap-
proach, there is no qualitative difference between symp-
toms of patients and symptoms occurring in the general 
population. The difference is merely quantitative and 
also regards the associated distress as well as the impact 
on daily life. This approach has been taken in the Dutch 
NEMESIS (Netherlands Mental Health Survey and Inci-
dence Study), which demonstrated a high incidence of 
delusions and hallucinations in the general population 
 [64] . We will now apply both of these approaches to neg-
ative symptoms.
 Factor-analytic studies of schizotypy questionnaires 
and interviews have produced a three-factor solution 
with positive, negative and disorganized components  [65, 
66] . The fact that this factor structure resembles the 
three-syndrome model of schizophrenia has been inter-
preted as evidence for continuity between these schizo-
phrenic and schizotypal symptoms. While there is some 
debate about the disorganization factor, there is compel-
ling evidence for a robust negative schizotypy factor, al-
Psychosis
Negative
symptoms
Cognitive
deficits
Depression
Mania
Psychosis
Negative
symptoms
Cognitive
deficits
Depression
Mania
a b
 Fig. 2. Multidimensional model of symp-
tom dimensions in the mood-psychotic 
disorder spectrum according to van Os 
[59, 60].  a Example of a patient with high 
expression on depression and negative 
symptom dimensions. This constellation 
could account for depressive patients ful-
filling deficit syndrome criteria.  b A high 
expression on the negative (and cognitive) 
symptom dimensions can occur indepen-
dently of the psychosis dimension. Thus, a 
patient with a deficit syndrome would not 
have more severe symptoms in general, but 
certainly on the negative symptom dimen-
sion. 
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though different terms have been applied  [67] . In addi-
tion, negative schizotypy shows associations with quality 
of life and neurocognition that are comparable to those 
observed in patients with schizophrenia  [68, 69] . Anoth-
er line of research with respect to the continuity debate 
concerns the relationship between premorbid personality 
and symptoms of psychotic disorders. Cuesta et al.  [70, 
71] have shown that negative symptoms are associated 
with schizoid personality traits prior to illness onset. 
Their definition of schizoid traits is related to negative 
schizotypy as used in other studies.
 It has to be noted that the symptoms subsumed under 
negative schizotypy depend on the scale used and the 
population studied. Critically, in some of these studies, 
negative schizotypy covers items that are only indirectly 
related to schizophrenic negative symptoms. Question-
naires will necessarily have a stronger focus on subjective 
experience than on observed behavior, which is com-
monly emphasized in rating scales for schizophrenia. But 
negative factors derived from schizotypy interviews have 
also included items not directly related to negative symp-
toms. For example, in the Structured Interview for 
Schizotypy-Revised, these items encompass social isola-
tion, social anxiety, introversion, restricted affect, refer-
ential thinking and suspiciousness  [72] . A good example 
of these challenges is a recent study employing the Ox-
ford-Liverpool Inventory of Feelings and Experiences, a 
questionnaire that focuses on anhedonia as the sole neg-
ative schizotypal symptom  [73] . Not surprisingly, the 
study failed to find a significant correlation between the 
introversive anhedonia factor and SANS global scores in 
patients with schizophrenia.
 Strong evidence for a continuum comes from the 
Roscommon Family Study  [74] . The authors found that 
positive and negative symptoms in patients with schizo-
phrenia spectrum disorders predicted corresponding 
schizotypal symptoms in their relatives. This finding is 
interesting because it strongly suggests that there is an 
etiologic continuum. In other words, negative (and posi-
tive) symptoms are determined by similar familial etio-
logic factors in patient and nonpatient groups. In sum-
mary, there is strong evidence for a robust negative 
schizotypy construct. Whether these schizotypal symp-
toms lie on a continuum with schizophrenic negative 
symptoms is still a matter of debate and will require stud-
ies assessing both symptoms in the same population.
 As introduced above, another approach to negative 
symptoms in the general population would be based on 
similar symptoms occurring in both patient and nonpa-
tient groups. The group difference would then be regard-
ed as a mere question of quantity and associated distress. 
So far, this line of research has had a strong focus on pos-
itive symptoms. Nevertheless, investigations with the 
CAPE (Community Assessment of Psychic Experiences) 
have provided evidence for a negative symptom factor in 
the general population  [75] . In addition, the CAPE nega-
tive dimension correlates with the Brief Psychiatric Rat-
ing Scale negative dimension, providing a first hint for 
continuity  [76] . However, the relationship with more 
comprehensive negative symptom rating scales such as 
the SANS has not been addressed.
 One major problem in these comparisons is that clin-
ical negative symptom rating scales are interview based 
and rely at least in part on behavioral ratings by the in-
terviewer. Few studies have employed clinical assess-
ments of negative symptoms in participants drawn from 
the general population and have generally yielded a rela-
tively low prevalence  [77] . However, it is a critical issue 
whether these clinical rating scales are sensitive to detect-
ing negative symptoms in nonpatient groups. Even 
though this approach conceives of the symptoms as qual-
itatively similar, clinical scales might require a high 
threshold to detect a symptom at all. Therefore, instru-
ments for assessing negative symptoms over the whole 
range from healthy subjects to patients are urgently need-
ed. This is necessary to expand the preliminary evidence 
for negative symptoms in the general population that 
might be qualitatively similar to those in schizophrenia.
 Implications of a Dimensional Approach 
 In the previous sections, we have presented evidence 
that negative symptoms occur in disorders other than 
schizophrenia and that they occur in the general popula-
tion at least in an attenuated form. Thus, we suggest a 
dimensional distribution across the mood-psychotic dis-
order spectrum and along a continuum between manifest 
disorders, risk status and health ( fig. 3 ). It is clear that the 
evidence presented cannot constitute definite proof of a 
dimensional distribution of negative symptoms.
 Further diagnostic studies including patient samples 
across disease categories and in the general population 
are needed. One important issue for this type of research 
regards the assessment instruments. The available assess-
ment instruments with a specific focus on negative symp-
toms were validated for patients with schizophrenia, and 
this continues to be the case for the instruments resulting 
from the MATRICS initiative  [21] . This might not result 
in a serious problem with respect to the constructs as-
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sessed, which seem to be stable across disease categories. 
However, it needs to be addressed whether the available 
instruments provide adequate sensitivity to mild varia-
tions in these symptoms.
 Even when studies in appropriate samples are con-
ducted with appropriate scales, there remain method-
ological problems of arriving at a statistically sound dif-
ferentiation between dimensional and categorical con-
cepts (see Haslam  [78] and Kraemer et al.  [79] for 
discussion). The controversy has been pointedly put as 
just a different way of looking at the same data, and these 
authors have suggested that the appropriate approach 
should be selected according to the respective purpose 
 [79, 80] . We argue that the evidence reviewed certainly 
justifies an exploration of the dimensional approach with 
respect to both its clinical and scientific utility.
 First of all, a negative symptom dimension within a 
multidimensional model of the mood-psychotic disorder 
spectrum has important implications for research and 
treatment. Current research has already begun to shift 
from neurocognitive models of disease entities to models 
of symptom formation. However, if one takes the multi-
dimensional model seriously, neurocognitive correlates 
of symptom dimensions should not be investigated with-
in a disease category but across disease categories. A sim-
ilar argument regards current treatment developments, 
which turn towards a more differentiated targeting of 
symptoms instead of a disease like schizophrenia  [81] . 
Here, a shift towards drug development for negative 
symptoms across the mood-psychotic disorder spectrum 
could be a promising step.
 Second, a dimensional distribution between severe 
symptom expression and health takes these consider-
ations even further. Importantly, this should lead to a 
neurocognitive framework for understanding symptoms 
as variations of normal mental processes  [82] . Current 
research already adopts this approach to some extent by 
beginning to use common models to address the relation-
ship between symptom or personality dimensions and 
neurocognitive correlates. However, the empirical work 
usually addresses these relationships separately in pa-
tients or healthy participants. Again, if one takes the di-
mensional approach seriously, one should address this is-
sue across the spectrum from healthy subjects to those 
with severe symptom expression. As mentioned above, a 
critical point for this approach will be the need for assess-
ment instruments that can cover the whole severity spec-
trum of symptom expression.
 Finally, this dimensional approach should also encour-
age psychotherapeutic approaches to the treatment of 
negative symptoms. Understanding symptoms as varia-
tions of normal processes opens an avenue for cognitive 
and behavioral interventions. Such an approach has been 
an important condition for developing cognitive-behav-
ioral therapy for persistent positive symptoms, which are 
thought to be caused among other things by variations in 
attributional style, attention allocation and mental state 
attribution  [83, 84] . The effect of broader cognitive-be-
havioral therapy programs on negative symptoms has 
been promising  [85, 86] . However, results of the first large-
scale trial with negative symptoms as the primary focus 
do not seem to show specific effects  [87, 88] . This might in 
part be accounted for by the unexpected improvement in 
the active control group, and final results have not yet 
been published. Here, it is a critical issue that – in com-
parison with cognitive models of delusion formation – 
current neurocognitive models of negative symptoms are 
rather crude and far less comprehensive. Thus, we are still 
quite far away from understanding negative symptoms as 
variations of normal mental processes. Within a dimen-
sional framework, further development of these models 
will not only be of high scientific interest, but should have 
a strong impact on approaches to treatment. 
Schizophrenia Schizoaffective Affective
Need for care
At risk
Healthy
 Fig. 3. We propose that negative symptoms are dimensionally dis-
tributed across the mood-psychotic disorder spectrum and along 
a continuum between manifest disorders, risk status and health. 
Probability and intensity of negative symptoms are marked as 
darkness of shading. Patients with schizophrenia showing prom-
inent and enduring negative symptoms would be located in the 
top left of the graph, but nevertheless on a continuum with all 
other groups. The dashed lines are arbitrary and do not reflect a 
categorical transition. 
 Kaiser  /Heekeren  /Simon  Psychopathology 2011;44:345–353352
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